141 related articles for article (PubMed ID: 8514453)
1. Prediction of response to endocrine therapy in breast cancer using immunocytochemical assays for pS2, oestrogen receptor and progesterone receptor.
Luqmani YA; Ricketts D; Ryall G; Turnbull L; Law M; Coombes RC
Int J Cancer; 1993 Jun; 54(4):619-23. PubMed ID: 8514453
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical and biochemical analysis of the oestrogen regulated protein pS2, and its relation with oestrogen receptor and progesterone receptor in breast cancer.
Detre S; King N; Salter J; MacLennan K; McKinna JA; Dowsett M
J Clin Pathol; 1994 Mar; 47(3):240-4. PubMed ID: 8163696
[TBL] [Abstract][Full Text] [Related]
3. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.
Soubeyran I; Quénel N; Coindre JM; Bonichon F; Durand M; Wafflart J; Mauriac L
Br J Cancer; 1996 Oct; 74(7):1120-5. PubMed ID: 8855985
[TBL] [Abstract][Full Text] [Related]
4. Immunoradiometric detection of pS2 and total cathepsin D in primary breast cancer biopsies: their correlation with steroid receptors.
Marsigliante S; Biscozzo L; Correale M; Paradiso A; Leo G; Abbate I; Dragone CD; Storelli C
Br J Cancer; 1994 Mar; 69(3):550-4. PubMed ID: 8123486
[TBL] [Abstract][Full Text] [Related]
5. [Immunohistochemical detection of pS2 protein in paraffin sections of breast carcinoma tissue. Comparison with results of an immunoradiometry assay].
Ahr A; Scharl A; Göhring UJ; Crombach G; Stoffl M
Pathologe; 1995 Jul; 16(4):278-84. PubMed ID: 7667210
[TBL] [Abstract][Full Text] [Related]
6. pS2 expression and response to hormonal therapy in patients with advanced breast cancer.
Schwartz LH; Koerner FC; Edgerton SM; Sawicka JM; Rio MC; Bellocq JP; Chambon P; Thor AD
Cancer Res; 1991 Jan; 51(2):624-8. PubMed ID: 1985778
[TBL] [Abstract][Full Text] [Related]
7. Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer.
Stonelake PS; Baker PG; Gillespie WM; Dunn JA; Spooner D; Morrison JM; Bundred NJ; Oates GD; Lee MJ; Neoptolemos JP
Eur J Cancer; 1994; 30A(1):5-11. PubMed ID: 8142164
[TBL] [Abstract][Full Text] [Related]
8. Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas.
Hurlimann J; Gebhard S; Gomez F
Histopathology; 1993 Sep; 23(3):239-48. PubMed ID: 8225242
[TBL] [Abstract][Full Text] [Related]
9. PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.
Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Bari M; Leon AE; Vinante O; Bruscagnin G
Br J Cancer; 1993 Aug; 68(2):374-9. PubMed ID: 8347494
[TBL] [Abstract][Full Text] [Related]
10. Biphasic Scatchard plots of oestrogen receptors are associated with low pS2 levels in human breast cancers.
Marsigliante S; Biscozzo L; Leo G; Storelli C
Cancer Lett; 1999 Sep; 144(1):17-23. PubMed ID: 10503873
[TBL] [Abstract][Full Text] [Related]
11. Prediction of relapse and survival in breast cancer patients by pS2 protein status.
Foekens JA; Rio MC; Seguin P; van Putten WL; Fauque J; Nap M; Klijn JG; Chambon P
Cancer Res; 1990 Jul; 50(13):3832-7. PubMed ID: 2354435
[TBL] [Abstract][Full Text] [Related]
12. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer.
Johnston SR; Saccani-Jotti G; Smith IE; Salter J; Newby J; Coppen M; Ebbs SR; Dowsett M
Cancer Res; 1995 Aug; 55(15):3331-8. PubMed ID: 7614468
[TBL] [Abstract][Full Text] [Related]
13. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer.
Daffada AA; Johnston SR; Smith IE; Detre S; King N; Dowsett M
Cancer Res; 1995 Jan; 55(2):288-93. PubMed ID: 7812959
[TBL] [Abstract][Full Text] [Related]
14. pS2 protein and steroid hormone receptors in invasive breast carcinomas.
Koerner FC; Goldberg DE; Edgerton SM; Schwartz LH
Int J Cancer; 1992 Sep; 52(2):183-8. PubMed ID: 1521907
[TBL] [Abstract][Full Text] [Related]
15. Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node-negative breast cancer.
Cappelletti V; Coradini D; Scanziani E; Benini E; Silvestrini R; Di Fronzo G
Eur J Cancer; 1992; 28A(8-9):1315-8. PubMed ID: 1515241
[TBL] [Abstract][Full Text] [Related]
16. Quantitative analysis of p185(HER-2/neu) protein in breast cancer and its association with other prognostic factors.
Valerón PF; Chirino R; Vega V; Falcón O; Rivero JF; Torres S; León L; Fernández L; Pestano J; Díaz-Chico B; Díaz-Chico JC
Int J Cancer; 1997 Apr; 74(2):175-9. PubMed ID: 9133451
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of the cytosolic content of the pS2 protein in breast cancer].
Tamargo F; Vizoso F; Lamelas ML; Rodil A; Vérez P; Raigoso P; Mulero M; Vázquez J; Roiz C; Allende MT
Rev Esp Med Nucl; 2002 Feb; 21(1):28-33. PubMed ID: 11820999
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of the estrogen regulated pS2 protein in mammary tumors.
Pichon MF; Milgrom E
Crit Rev Oncol Hematol; 1993 Aug; 15(1):13-21. PubMed ID: 8240704
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.
Elledge RM; Green S; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; Martino S; Osborne CK
Int J Cancer; 2000 Mar; 89(2):111-7. PubMed ID: 10754487
[TBL] [Abstract][Full Text] [Related]
20. Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer.
Tong D; Schneeberger C; Czerwenka K; Schmutzler RK; Speiser P; Kucera E; Concin N; Kubista E; Leodolter S; Zeillinger R
Clin Cancer Res; 1999 Jun; 5(6):1497-502. PubMed ID: 10389938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
